Sales of delta-8 THC and other psychoactive cannabinoids that are chemically modified from natural cannabinoids are booming. Sellers claim that these substances are federally legal under the 2018 Farm Act. But are they? This webinar will first delve into the chemistry of these modified cannabinoids, how they are derived, possible safety concerns, and their similarities and differences from delta-9 THC. Speakers will then discuss the legal status of these relatively new cannabinoids under FDA, USDA, and DEA rules, the evolving nature of state bans, and the potential influence on policy discussions about other cannabis products.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Rod Kight, Founder, Kight Law Office and Attorney, Hemp Industries Association
Michael McGuffin, President, American Herbal Products Association
Jonathan S. Miller, Member, Frost Brown Todd LLC and General Counsel, U.S. Hemp Roundtable
Deborah Miran, Consultant, DMiran Consulting
Moderated by Delia Ann Deschaine, Partner, Epstein Becker & Green, PC

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content